OLIVER LAGORE VANVALIN INVESTMENT GROUP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
OLIVER LAGORE VANVALIN INVESTMENT GROUP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$27,779
-39.3%
612
-24.9%
0.01%
-35.3%
Q2 2023$45,754
+24.1%
8150.0%0.02%
+6.2%
Q1 2023$36,862
-10.7%
815
-19.7%
0.02%
-30.4%
Q4 2022$41,260
-69.4%
1,015
-50.8%
0.02%
-73.6%
Q3 2022$135,000
-6.2%
2,065
-12.7%
0.09%
+3.6%
Q2 2022$144,000
+94.6%
2,365
+103.0%
0.08%
+68.0%
Q1 2022$74,0001,1650.05%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2022
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders